Effects of sulindac, sulindac metabolites, and aspirin on the activity of detoxification enzymes in HT-29 human colon adenocarcinoma cells

Cancer Letters

Volumn 147, Issue 1-2, 1999, Pages 95-100

  Patten, Emma J ^a   DeLong, Mary J ^a  

^a Nutrition and Health Sciences Program   (United States)

Author keywords

Chemoprevention; Enzyme inducer; Glutathione S transferase; NAD(P)H:quinone reductase; Nonsteroidal anti inflammatory drug

Indexed keywords

ACETYLSALICYLIC ACID; DRUG METABOLITE; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HT29; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DETOXIFICATION; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; GLUTATHIONE TRANSFERASE; HT29 CELLS; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); SULINDAC; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0032730016     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00282-7     Document Type: Article

References (58)

1. Gridley G., McLaughlin J., Ekbom A., Klareskog L., Adami H., Hoover R., Fraumeni J.J. Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer Inst. 85:1993;307-310.
2. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., Ascherio A., Willett W.C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121:1994;241-246.
3. Brogden R.N., Hell R.C., Speight T.M., Avery G. Sulindac: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs. 16:1978;97-114.
4. Thun M.J. NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol. Clin. N. Am. 25:1996;333-348.
5. Rosenberg L., Palmer J.R., Zauber A.G., Warshauer M.E., Stolley J.D., Shapiro S.A. A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl. Cancer Inst. 83:1991;355-358.
6. Thun M.J., Namboodiri M.M., Heath C.W. Aspirin use and reduced risk of fatal colon cancer. New Engl. J. Med. 325:1991;1593-1596.
7. Thun M.J., Namboodiri M.M., Calle E.E., Flanders J.D., Heath C.W. Aspirin use and risk of fatal cancer. Cancer Lett. 53:1993;1322-1327.
8. Kune G.A., Kune S., Watson L.F. Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 48:1988;4399-4404.
9. Reddy B., Rao C., Rivenson A., Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis. 14:1993;1493-1497.
10. Davis A.E., Patterson F. Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model. Aust. N.Z. J. Med. 24:1994;301-303.
11. Mereto E., Frencia L., Gjia M. Effect of aspirin on incidence and growth of aberrant crypt foci induced in rat colon by 1,2-dimethylhydrazine. Cancer Lett. 76:1994;5-9.
12. Rao C.V., Rivenson A., Simi B., Zang E., Kelloff G., Steel V., Reddy B.S. Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent. Cancer Res. 55:1995;1464-1472.
13. Moorghen M., Ince P., Finney K.J., Sunter J.P., Appleton D.R., Watson A.J. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J. Pathol. 156:1988;341-347.
14. Earnest D.L., Hixson L.J., Alberts D.S. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J. Cell. Biochem. 161:(Suppl.):1992;136-166.
15. Smith W.L., Marnett L.J. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim. Biophys. Acta. 1083:1991;1-17.
16. Webb D.R., Osheroff P.L. Antigen stimulation of prostaglandin synthesis and control of immune response. Proc. Natl. Acad. Sci. USA. 73:1976;1300-1304.
17. Craven P.A., Saito R., DeRubertis F.R. Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J. Clin. Invest. 72:1983;1365-1375.
18. Lupescu A. Enhancement of carcinogenesis by prostaglandins. Nature. 272:1978;634-636.
19. Lynch N.R., Castes M., Astoin M., Salomon J.C. Mechanism of inhibition of tumor growth by aspirin and indomethacin. Br. J. Cancer. 38:1978;503-512.
20. Marnett L.J. Aspirin and potential role of prostaglandins in colon cancer. Cancer Res. 52:1992;5575-5589.
21. Smith W.L. Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol. 263:1992;F181-F191.
22. Piazza G.A., Alberts D.S., Hixson L.J., Paranka N.S., Li H., Finn T., Bogert C., Guillen J.M., Brendel K., Gross P.H., Sperl G., Ritchie J., Burt R.W., Ellsworth L., Ahnen D.J., Pamukcu R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57:1997;2909-2915.
23. Thompson C., Jiang C., Lu J., Mehta R.G., Piazza G.A., Paranka N.S., Pamukcu R., Ahnen D.J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 57:1997;267-271.
24. Beckett G.J., Hayes J.D. Glutathione-S-transferases: biomedical applications. Adv. Clin. Chem. 30:1993;281-380.
25. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and contribution of the isoenzymes to cancer chemoprevention and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30:1995;445-600.
26. Nijhoff W.A., Groen G.M., Peters W.H.M. Induction of rat hepatic and intestinal glutathione S-transferases and glutathione by dietary naturally occurring anticarcinogens. Int. J. Oncol. 3:1993;1131-1139.
27. Joseph P., Xie T., Xu Y., Jaiswal A.K. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase): expression, regulation and role in cancer. Oncol. Res. 6:1994;525-532.
28. Singh S.V., Pan S.S., Srivastava S.K., Xia H., Hu X., Zaren H.A., Orchard J.L. Differential induction of NAD(P)H:quinone oxidoreductase by anti-carcinogenic organosulfides from garlic. Biochem. Biophys. Res. Commun. 244:1998;917-920.
29. Talalay P., DeLong M.J., Prochaska H.J. Molecular mechanisms in protection against carcinogenesis. Cory J.G., Szentivanyi A. Cancer Biology and Therapeutics. 1987;197-216 Plenum, New York.
30. Chasseaud L.F. The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv. Cancer Res. 29:1979;176-274.
31. Ernster L. DT diaphorase. Estabrook R.W., Pullman M.E. Methods in Enzymology. 1967;309-317 Academic Press, New York.
32. Wattenberg L.W. Chemoprevention of cancer. Cancer Res. 45:1985;1-8.
33. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione S-transferases. J. Biol. Chem. 249:1974;7130-7139.
34. Turner D., Berkel H.J. Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer. Can. Med. Assoc. J. 149:1993;595-602.
35. Narisawa T., Sato M., Tani M., Kudo T., Guo A. Inhibition of development of methylnitrosurea-induced rat colon tumours by indomethacin treatment. Cancer Res. 41:1981;1954-1957.
36. Pollard M., Luckert P.H. Effect of piroxicam in primary intestinal tumours induced in rats by N-methylnitrosurea. Cancer Lett. 25:1984;117-121.
37. Rao C.V., Tokuno K., Rigotti J., Zang E., Kelloff G., Reddy B.S. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethlyornithine, 16α-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res. 51:1991;4528-4534.
38. Reddy B.S., Nayini J., Tokuno K., Rigotti J., Zang E., Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D,1,-α-difluromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res. 50:1990;2562-2568.
39. Reddy B.S., Maruyama H., Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumour development. Cancer Res. 47:1987;5340-5346.
40. Pollard M., Luckert P.H., Schmidt M.A. The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett. 21:1983;57-61.
41. Kudo T., Narisawa T., Abo S. Antitumour activity of indomethacin on methylazoxymethanol-induced large bowel tumours in rats. Jpn. J. Cancer Res. 71:1980;260-264.
42. Narisawa T., Satoh M., Sano M., Takahashi T. Inhibition of initiation and promotion by N-methylnitrosurea-induced colon carcinogenesis in rats by non-steroidal anti-inflammatory agent indomethacin. Carcinogenesis. 4:1983;1225-1227.
43. Pollard M., Luckert P.H. Prevention and treatment of primary intestinal tumours in rats by piroxicam. Cancer Res. 49:1989;6471-6473.
44. Craven P.A., DeRubertis F.R. Effects of aspirin on 1,-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis. 13:1992;541-546.
45. 2α. Proc. Natl. Acad. Sci. USA. 72:1975;2724-2728.
46. Rigas B., Goldman I.S., Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 122:1993;518-523.
47. Hubbard W.C., Alley M.C., McLemore T.L., Boyd M.R. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors. Cancer Res. 48:1988;4770-4775.
48. Aruoma O.I., Haliwell B. The iron-binding and hydroxyl radical scavenging action of anti-inflammatory drugs. Xenobiotica. 18:1988;459-470.
49. Piazza G.A., Kulchak Pahm A.L., Krutzsch M., Sperl G., Shipp Paranka N., Gross P.H., Brendel K., Burt R.W., Alberts D.S., Pamukcu R., Ahnen D.J. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55:1995;3110-3116.
50. Shiff S.J., Qiao L., Tsai L.-L., Basil R. Sulindac sulfide, as aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. 96:1995;491-503.
51. Waddell W.R., Loughry R.W. Sulindac for polyposis of the colon. J. Surg. Oncol. 24:1983;83-87.
52. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., Offerhaus G.J. Treatment of colonic adenomas with sulindac in familial adenomatous polyposis. New Engl. J. Med. 328:1993;1313-1316.
53. Van Lieshout E.M.M., Tiemessen D.M., Roelofs H.M.J., Peters W.H.M. Non-steroidal anti-inflammatory drugs enhance glutathione S-transferase theta levels in rat colon. Biochim. Biophys. Acta. 1381:1998;305-311.
54. Van Lieshout E.M.M., Tiemessen D.M., Peters W.H.M., Jansen J.B.M.J. Effects of nonsteroidal anti-inflammatory drugs on glutathione S-transferases of the rat digestive tract. Carcinogenesis. 18:1997;485-490.
55. Herrmann C., Block C., Geisen C., Haas K., Weber C., Winde G., Moroy T., Muller O. Sulindac sulfide inhibits Ras signaling. Oncogene. 17:1998;1769-1776.
56. Belinsky M., Jaiswal A.K. NAD(P)H:quinone oxidoreductase 1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metast. Rev. 12:1993;103-117.
57. Wang W., Higuchi C.M. Induction of NAD(P)H:quinone reductase by vitamins A, E, and C in Colo205 colon cancer cells. Cancer Lett. 98:1995;63-69.
58. Aruoma O.I., Haliwell B. The iron-binding and hydroxyl radical scavenging action of anti-inflammatory drugs. Xenobiotica. 18:1988;459-470.